Research progress on the mechanism of evodiamine against gastrointestinal tumor

• 作者: Chun-Jiao Fan Peng Huang Gui-Hua Huang Hua Qiu Xiao-Mei Zhang
• 来源期刊: 海南医科大学学报（英文版）
• 年，卷（期）: 2021,（10）
• 所属期刊栏目: Review and lectures
• 页码范围: 61-66
• 页数: 6页
• 语种: 英文

摘要

Evodiamine is an indole quinazoline alkaloid with anti-tumor activity, which may be developed into a drug for the treatment of tumor. It was found that evodiamine could inhibit or even block the signal pathways of Wnt/ β-catenin, mTOR, NF--κ B, PI3K/AKT, Hippo-YAP and BMP in many kinds of cancer cells, thus interfering with cell division and differentiation, increasing the rate of apoptosis, and down-regulating the expression of various cancer cell markers. Such as B-cell lymphoma 2 (Bcl-2), B-cell lymphoma super-large (Bcl-XL), cyclooxygenase 2 (COX-2), Survivin, vascular endothelial growth factor (VEGF) and matrix metallopeptidase 9 (MMP-9), which have a strong inhibitory effect on asymmetric division, malignant proliferation and angiogenesis of tumor cells. This paper summarizes evodiamine in digestive system tumors by regulating Wnt/ β-catenin, mTOR, PI3K/AKT, BMP and other signal pathways, interfering with cell division, differentiation and apoptosis, inhibiting the expression of tumor-related marker genes, and preventing tumor cell migration and invasion, so as to provide a basis for the clinical application and further research of evodiamine in the future.